Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$720.7K
11.42K shares
What this filing means
ZALEVSKY JONATHAN plans to sell 11.42K shares of NEKTAR THERAPEUTICS valued at approximately $720.7K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/30/2026ACC: 0001950047-26-006656
Officer· Chief R&D Officer
Since Oct 2019
11.42K
Shares to sell
$720.7K
Approx. market value
5.68K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months1
Restricted Stock Units
N/A
11/15/2020
5.68KTotal acquired5.68K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
11/15/2020 | Restricted Stock Units N/A | 5.68K | — |
| Total | 5.68K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
5.54K
Market value
$336.2K
6/15/2026
—Completed
Units to sell
199.00
Market value
$13.0K
5/19/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
5.68K
Market value
$371.5K
6/30/2026
Total
Units
11.42K
Value
$720.7K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
6/15/2026 | 5.54K | $336.2K | — | Completed |
5/19/2026 | 199.00 | $13.0K | — | Completed |
| Planned — Approximate Date | ||||
6/30/2026 | 5.68K | $371.5K | NASDAQ | Planned |
| Total | 11.42K | $720.7K | ||